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Abstract
It is well established that CD4
+ T cells play an important role in immunity to infections with retroviruses such as
HIV. However, in recent years CD4
+ T cells have been subdivided into several distinct populations that are
differentially regulated and perform widely varying functions. Thus, it is important to delineate the separate roles of
these subsets, which range from direct antiviral activities to potent immunosuppression. In this review, we discuss
contributions from the major CD4
+ T cell subpopulations to retroviral immunity. Fundamental concepts obtained
from studies on numerous viral infections are presented along with a more detailed analysis of studies on murine
Friend virus. The relevance of these studies to HIV immunology and immunotherapy is reviewed.
Introduction
CD4
+ T lymphocytes are a specialized subpopulation of T
cells that recognize antigenic peptides in the context of
MHC class II molecules. Historically, CD4
+ T cells have
been regarded as ‘helper’ T( T h )c e l l s ,s i n c eC D 4
+ T-cell
help is required for both the induction of neutralizing
antibodies by mature B cells and for the maintenance of
effective cytotoxic T cell (CTL) responses. In the mid-
1980s functional attributes were discovered that allowed
CD4
+ T cells to be subdivided into dichotomous subpo-
pulations of Th1 and Th2 cells [1].
Th1 cells are defined by their property to produce IFNg,
TNFa and IL-2 cytokines, and play critical roles in anti-
tumor immunity [2] and immune responses to many virus
infections including lymphocytic choriomeningitis virus
(LCMV) [3], influenza virus [4], vesicular stomatitis virus
(VSV) [5], polio virus [6], and murine g herpes virus [7].
Besides helper functions, Th1 cells also have important
effector functions. For example, in addition to their immu-
noregulatory activities, both IFNg and TNFa cytokines
mediate direct anti-viral activities as observed in murine
infections of LCMV [8], herpes simplex virus (HSV) [9],
vaccinia virus [10], measles virus (MV) [11] and Friend
virus (FV) [12]. Th1 cells may also have cytotoxic potential
as observed in a number of viral infections, including den-
gue virus [13], HSV [14], hepatitis B virus (HBV) [15], MV
[16], human herpesvirus 6 [17], HIV [18] and Epstein-Barr
virus (EBV) [19].
By contrast, Th2 cells secrete IL-4, IL-5, IL-9, IL-13 and
IL-25 when activated in response to bacterial, helminth or
parasitic pathogens such as Clostridium tetani, Staphylo-
coccus aureus, Streptococcus pneumonia, Pneumocystis
carinii, Schistosoma mansoni,a n dTrichinella spiralis [20].
Th2 cells provide help for B cells to produce IgM, IgA,
IgE, and IgG isotype antibodies, which form the effector
molecules of the humoral immune response [21].
The Th1/Th2 paradigm introduced by Mossman and
Coffman has been expanded by identification of other
CD4
+ T cell sub-populations. IL-17 secreting cells desig-
nated as Th17 cells [22,23] are important for resistance to
extracellular bacteria and fungi, but may also contribute to
allergic responses [24] and autoimmune pathogenesis in
diseases such as multiple sclerosis, rheumatoid arthritis,
psoriasis and inflammatory bowel disease [25]. Yet another
sub-population of CD4
+ T cells is the follicular helper T
(Tfh) cell. Upon antigenic stimulation, Tfh produce IL-21
and home to B cell follicles where they are essential for
the differentiation of B cells into germinal center B cells
and antibody secreting plasma cells [26,27].
Finally, there is a unique subset of CD4
+ T cells called
regulatory T cell (Tregs) subset that negatively regulates
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and immunopathology [28]. During many different types
of infection natural and/or induced Tregs expand to
control the pathogen-specific effector T cell response.
Evidence indicates that this negative control mechanism
is important in limiting T-cell-mediated collateral
damage that may occur during immune responses
against microbial pathogens. Along these lines, Tregs
inhibit the development of immunopathogenesis in
Hepatitis C virus (HCV) infections [29], HSV infections
[30,31], and FV infections [32]. On the other hand,
Treg-mediated suppression of immune responses may
delay pathogen clearance as observed in chronic HCV
[33-35], HIV [36], EBV [37], HSV [38], and FV [39]
infections. In the same context, Tregs also inhibit anti-
tumor immune responses and restoration of anti-tumor
immunity requires attenuation of Treg functions [40].
The general importance of CD4
+ T cells in human
health and immunity was dramatically displayed early in
the AIDS epidemic as patients presenting with reduced
CD4
+ T cell counts developed opportunistic infections.
CD4
+ T cells, the main targets for HIV infection, are
rapidly depleted during HIV infection [41,42], eventually
leading to the acquired immunodeficiency syndrome
known as AIDS. Loss of antiviral IFNg production by
CD4
+ T cells, as well as loss of direct cytotoxic activity
against infected cells [43-45], contribute to immunodefi-
ciency, but more important may be the loss of CD4
+
T cell helper activity. CD4
+ T cell help is necessary for
long-term CD8
+ T cell memory and the development of
high-avidity antibody responses, both of which are defi-
cient in HIV infections [46-48]. Another major factor con-
tributing to HIV-induced immunodeficiency is immune
system hyperactivation, which appears to be the result of
HIV-induced pathology in the gut-associated lymphoid tis-
sue [49,50]. Damage to the gastrointestinal tract early in
HIV infection allows immunostimulatory microbial pro-
ducts such as lipopolysaccharide to translocate into the
bloodstream [51]. The resulting non-specific activation of
immune cells can cause activation-induced cell death and
contribute to HIV-associated CD4
+ T cell depletion. This
dysregulation of the immune response not only reduces
the ability to mount pathogen-specific responses, but can
cause immunopathogenic effects. Dysregulation is further
exacerbated by the loss of CD4
+ Tregs, which would nor-
mally dampen immunopathogenic responses [52,53].
The reported loss of CD4
+ Tregs from the peripheral
blood in HIV patients [54], is associated with an accumu-
lation of these same cells in infected lymphatic tissues,
suggesting that Tregs either redistribute to infected tissues,
proliferate there, or both [36,55]. Tregs at the sites of
infection are associated with dysfunctional CD8
+ T cells
and can inhibit both HIV-specific CD4
+ and CD8
+ Tc e l l
responses in vitro [36,54,56]. Interestingly, HIV-infected
patients who exert control over virus loads have lower
Treg responses [52], suggesting that Tregs indeed contri-
bute to effector T cell dysfunction and inability to clear
the infection.
Acute HIV-1 infection is usually characterized by mild
flu-like symptoms and hence, only few patients are diag-
nosed with acute HIV infection. Thus, there is limited
opportunity to study the early immunological responses
to HIV infection. Another limitation in HIV research is
the lack of a tractable small animal model susceptible to
HIV infection. The most widely used model is the infec-
tion of macaques with simian immunodeficiency virus
(SIV), which is closely related to HIV, and an enormous
amount of knowledge has been gained from studies in
this model. However, there are limitations in the studies
that can be done in non-human primates as compared to
a mouse model. For example, there are no colonies of
congenic, transgenic, or targeted gene knockout maca-
ques available for study. Since there is no perfect solution
for scientists to study HIV infections, the approach has
been to gain information from studies in humans, non-
human primates, and also mouse models, which are use-
ful for elucidating fundamental concepts in retroviral
immunology that may have relevance to HIV infections
in humans.
A mouse virus that has been particularly informative is
the Friend retrovirus, which has provided information
regarding basic mechanisms of immunological control and
escape in both acute and persistent retroviral infections.
Studies of mice infected with FV have revealed a complex
balance of immune responses induced by at least two sub-
sets of CD4
+ T cells with opposing effects. On one hand,
CD4
+ Tfh and Th1 cells coordinate B cell and CD8
+ Tc e l l
immune responses, and additionally induce direct anti-
viral effects fortifying the immunological control of FV
[57-59]. On the other hand, CD4
+ Tregs down-regulate
the immune responses of CD4
+ Th cells [32,58] and CD8
+
CTLs [39,60-62] thus, prolonging the recovery from acute
FV infection, and allowing the establishment of a chronic
infection. The interplay of different subsets of CD4
+ T
cells in FV infection and the relevance to HIV infection in
humans will be discussed in this review.
Friend retrovirus infection of mice
FV was isolated from leukemic mice by Charlotte Friend
[63] and has since been used for identifying genes that
control susceptibility to viral infection and virus-induced
cancer [64]. FV is a retroviral complex comprising
Friend murine leukemia virus (F-MuLV), a replication
competent helper virus that is nonpathogenic in adult
mice, and spleen focus-forming virus (SFFV), a replica-
tion-defective virus responsible for pathogenesis [65].
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being packaged in F-MuLV-encoded particles produced
in cells co-infected by both viruses. FV infection induces
lethal erythroleukemia in susceptible strains of mice
[65]. Recovery from FV-induced disease partly depends
upon genes mapped to the MHC (H-2) region on chro-
mosome 17 of the mouse. Resistance of adult mice
against FV-induced disease is determined by the pre-
sence of the ‘b’ alleles at the H-2D and H-2A regions,
important for the induction of rapid and strong FV-spe-
cific CTL and CD4
+ T-cell responses, respectively [66].
Mice that are resistant to FV-induced disease are homo-
zygous for the ‘b’ allele at the H-2A region and display a
higher magnitude of CD4
+ T-cell responses than FV-
susceptible mice that have none or only one ‘b’ allele in
the H-2A region [58]. However, despite protection from
FV-induced leukemia, resistant mice are unable to clear
the virus completely and remain persistently infected for
life [64,67].
In the recent past it was discovered that mouse-passaged
FV stocks also contained lactate dehydrogenase-elevating
virus (LDV), an endemic mouse virus. LDV interferes with
anti-FV immune responses compromising early recovery
from FV infection [68,69]. Subsequently, much of the data
generated with virus stocks containing LDV have been
repeated with FV/LDV- stocks, and in this review we dis-
cuss results from experiments performed with both FV/
LDV+ and FV/LDV- virus stocks.
The role of CD4
+ T cells in FV infection and
vaccination
Specificity of CD4
+ T cells in FV infection
CD4
+ T cells are indispensable for natural immunity
against FV since the absence of CD4
+ T cells during the
acute or chronic phase of FV infection causes loss of con-
trol over FV replication in resistant mice [57-59,70]. CD4
+ T cells mediate immunity during FV as well as FV/LDV
+ co-infection, as comparable results are obtained in
CD4-depletion experiments using FV alone or FV/LDV+
infected mice [58,70]. Use of congenic recombinant mice
allowed the identification of two CD4
+ T cell epitopes of
the F-MuLV gp70 Env molecule that stimulate CD4
+ T
cell responses in FV infected mice. One of the epitopes
lies in the N-terminal region of F-MuLV env122-141
(DEPLTSLTPRCNTAWNRLKL) and is presented in the
context of H-2 IA
b molecules while the second epitope is
in the C-terminal region of F-MuLV env462-479 (HPPSY-
VYSQFEKSYRHKR) and is presented in the context of
H-2 IE
b/d molecules [71-73]. In addition, an A
b/k or E
b/k
restricted CD4
+ T cell epitope in the p15 (MA) region of
the F-MuLV gag83-97 (IVTWEAIAVDPPPWV) protein
[74] is associated with the induction of effective CD4
+T
cell immune responses against FV challenge.
Role of CD4
+ T cells in vaccine-induced protection
against FV
Protection from FV infection can be elicited by several
different types of vaccines including killed and attenuated
viruses, viral proteins, peptides, and recombinant vaccinia
or adenovirus vectors expressing FV genes. Vaccination
with recombinant vaccinia viruses using different combi-
nations of FV protein fragments identified protective epi-
topes in the F-MuLV Gag and Env proteins, although
vaccination with F-MuLV Env vectors protects better
against infection than vaccination with a gag vector alone
[75,76]. These studies were done in congenic mice to
eliminate host genes as variables affecting protection.
Adenovirus vectors expressing F-MuLV Env and Gag
also induce varying degrees of protection against FV,
which can be significantly improved by adding vectors
that not only expresses F-MuLV proteins but also dis-
played F-MuLV gp70 on the viral surface [77]. In these
experiments, protection correlated with an enhanced
neutralizing antibody and FV-specific CD4
+ T cell
response after virus challenge. Immunization with syn-
thetic peptide vaccines containing the CD4
+ Tc e l le p i -
topes env121-141 or env462-479 from the gp70 Env
glycoprotein of F-MuLV induces protection in most of
the vaccinated mice [78]. Surprisingly, it was suggested
that the protective effect of the CD4 epitope vaccine was
dependent on NK cells, as NK cell depletion after vacci-
nation abolished the effect of peptide immunization [79].
Studies using congenic and congenic recombinant mice
have demonstrated that the MHC background of the
mice used for immunization plays an important role in
determining the efficacy of vaccines [64,80]. As expected,
only mice expressing MHC class II alleles such as H-2A
b,
which can present the immunodominant CD4
+ T cell
epitopes are protected when immunized with vaccinia
virus recombinants expressing F-MuLV Env protein
[71,81]. Of note, recovery of immunized mice from chal-
lenge with pathogenic FV requires induction of neutraliz-
ing antibodies (IgG) and virus-specific T cell responses
[75,81]. The requirement for complex immune responses
in inducing protection against FV was confirmed using a
live attenuated FV vaccine. Nonpathogenic F-MuLV,
which replicates poorly in adult mice, was used as attenu-
ated vaccine. Further attenuation of the virus was
achieved by crossing the Fv-1 genetic resistance barrier
in mice [82]. Adoptive transfer experiments between con-
genic mice illustrated that the sterilizing immunity
induced by this vaccine depends on virus-specific CD4
+
and CD8
+ T cell as well as on B cell responses [83].
Whereas the CD8
+ T cells and antibodies have some pro-
tective activity on their own, vaccine-primed CD4
+
T cells alone did not induce protection [84], suggesting
that their role in protection against FV is mainly to
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ever, high numbers of FV-specific CD4
+ T cells mediate
direct antiviral effects even in the absence of effector
CD8
+ T or B cells [59].
Helper functions of CD4
+ T cells in FV infection
Antibodies are critical for most effective antiviral immune
responses and utilize a number of different mechanisms to
mediate protection. These include blockade of receptor-
binding proteins on viruses, lysis of virally infected cells,
and lysis of the viruses themselves [85-88]. Passive immu-
nization studies demonstratedt h a ta n t i b o d i e sa l o n e ,a t
concentrations inducible by vaccines, reduce virus loads in
FV infected mice but cannot completely prevent infection
[83,89]. At these physiological concentrations of antibody,
the mice also require T cell-mediated immune responses
for protection. The development of effective antibody
responses against most viruses, including FV requires help
from CD4
+ T cells [58,90], and recent evidence indicates
that a specialized subset called Tfh cells is essential for B
cell help (Figure 1).
The differentiation of Tfh is controlled by expression of
the B cell lymphoma 6 (Bcl-6) gene [91-93], and Tfh
express several distinct molecules involved in B cell help
including CXCR5, PD-1, ICOS, CD40L and OX40. Recent
analysis of the differentiation of virus-specific CD4
+ T
cells during FV infection revealed a prominent Tfh profile
[94]. At the peak of the response, up to 40% of the virus-
specific CD4
+ T cells in the spleen were defined as Tfh by
expression of a combination of surface markers (CXCR5,
PD-1 and ICOS), transcription factors (Bcl-6) and by their
cytokine profile (IL-21). In contrast, little differentiation of
virus-specific CD4
+ T cells towards Th2, Treg, or Th17
subsets was observed. These studies were made possible
FV-infected 
cells
IFN-γ
help
FV-induced 
splenomegaly
Maintenance &
Survival
Acute phase of Friend Virus infection
(0-4 weeks post infection) 
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IFN-γ, Perforin, 
Granzymes
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CD8
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CD4
Tregulatory
CD4
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Figure 1 Distinct populations of CD4
+ T cells regulate the virus-specific immune response during acute Friend Retrovirus infection.
CD4
+ helper T cells and follicular helper T cells augment virus-specific cytotoxic T cell and antibody responses. In addition, a subpopulation of
effector CD4
+ T cells directly inhibits virus replication. However, at the same time natural regulatory T cells expand and start to suppress effector
T cell responses, which interferes with control of virus replication. (Arrows indicate enhancement of responses, whereas blocked lines indicate
inhibition).
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chain specific for FV. The strong Tfh differentiation of
FV-specific CD4
+ T cells can be a result of the specific
cytokine environment that this infection creates, as it is
likely to be the case for Th1 differentiation. Also, the effi-
cient infection of B cells by FV [68,95], which then present
FV antigens to specific CD4
+ T cells, may contribute to
enhance Tfh differentiation [96].
Although Tfh differentiation probably requires high-
avidity TCR interactions with antigen-presenting cells
following peptide immunization [97], no such require-
ment is observed during acute FV infection [94]. This
finding indicates that levels and/or persistence of antigen
presentation during viral infections may exceed those
achieved by peptide immunization, and therefore the
requirement for high-avidity TCR signaling is bypassed.
In HIV infections, the relative control of viremia is asso-
ciated with the presence of IL-21-producing CD4
+
T cells [98]. Interestingly, evidence suggests that IL-21-
producing CD4
+ T cells may be critical for the mainte-
nance of CD8
+ T cell responses during chronic virus
infections [99-101], although it remains to be determined
whether in all these cases IL-21 is produced by Tfh cells
or another T cell subset.
It is known that CD4
+ T cells are generally important
for the clonal expansion, development of effector func-
tion, and the generation of long-term memory CD8
+
T cells [102]. The requirement of CD4
+ T cell-help for
primary CD8
+ T cell responses is determined by the nat-
ure of the infectious agent and the inflammatory milieu
formed by the pathogen [103-105]. Although T cell help
may be dispensable in the priming phase of the CD8
+
T cell response, it is essential in the generation and main-
tenance of long-lived memory CD8
+ T cells [106-109],
and the function of CD8
+ T cells during chronic infection
[110]. During the first two weeks of acute FV infection
the priming and expansion of CD8
+ T cells occurs inde-
pendently of CD4
+ T-cell help [68]. In contrast, CD4
+
T cells are required for the maintenance of effector and
memory FV-specific CD8
+ T cells during the recovery
phase of FV infection [58] (Figure 1). The situation is
slightly different in HIV-1 infections where the develop-
ment of effector CD8
+ T cell responses is compromised
in the absence of help from CD4
+ T cells [47]. As men-
tioned above, there appears to be a role for CD4
+ T cell-
produced IL-21 in the development of HIV-specific
CD8
+ T cell responses [98], and IL-21 has also been
shown to be an important cytokine in the maintenance of
CD8
+ T cell functionality during chronic viral infections
[99-101].
Direct anti-viral functions of CD4
+ T cells against FV
In addition to classical helper functions, CD4
+ T cells
possess direct effector functions important in controlling
infectious agents. As demonstrated in vitro,I F N g
secreted by CD4
+ Th1 cells during FV infection is a key
component involved in the direct anti-viral effects of
CD4
+ T cells [12]. Studies in genetic knockout mice and
mice depleted of IFNg-producing CD4
+ T cells suggest
an especially important role in the long-term control of
persistent FV infection [12,57,111,112] (Figure 2). FV-
specific CD4
+ T cells from CD4
+ TCRb-transgenic mice
with a TCRb chain specific for the F-MuLV env122-141
epitope rapidly expand in an antigen-dependent manner
when adoptively transferred into acutely infected mice.
The cells differentiate into Th1-type effector CD4
+
T cells that produce IFNg [58,59] (Figure 1). Adoptive
transfers of FV-specific CD4
+ T cells into FV-infected
mice that are either lymphocyte-deficient or depleted,
protect from acute disease even in the absence of cyto-
toxic T cell or antibody responses [59]. These results
indicate potent and direct anti-viral effects by CD4
+
T cells. Protection is not solely based on IFNg produc-
tion, since protection against acute disease is also seen
in IFNg receptor deficient mice [59]. However, FV-speci-
fic CD4
+ T cells only protect immunodeficient mice
against acute disease, and all animals eventually suc-
cumb to the infection in the absence of CD8
+ T cells
and B cells [59]. In HIV infection too, anti-viral effector
responses in HIV-1-infected long-term non-progressors
are associated with increased levels of IFNg, the chemo-
kine RANTES, and the macrophage inflammatory proteins
MIP-1a and MIP-1b that are produced by virus-specific
CD4
+ T cells [113]. The rare individuals who display
immunological control over HIV not only possess effective
CD8
+ CTL [114,115], but also contain multiple CD4
+
T cell clones with the characteristics of highly efficient
effector cells that have high-avidity to HIV gag peptides
and produce IFNg [116]. A most interesting and poorly
understood aspect of HIV controllers is that they can
maintain cell-mediated immune responses over long peri-
ods of chronic infection, a situation where most cell-
mediated responses become exhausted and ineffective.
In addition to providing help and secreting antiviral
factors, it has also been shown that CD4
+ T cells can
develop the capacity to lyse infected cells. Although most
data come from cell lines and CD4
+ Tc e l lc l o n e s ,i th a s
been shown that CD4
+ T cells specific for LCMV [117],
influenza [118] have cytotoxic activity in vivo.F u r t h e r -
more, cytotoxic CD4
+ T cells from the peripheral blood
of individuals infected withH I V - 1 ,i n f l u e n z a ,E B Vo r
CMV display cytotoxic activity directly ex vivo [119-124].
One obvious limitation on CD4
+ T cell-mediated cyto-
toxic activity is that cognate antigen is only recognized
on target cells that express MHC class II molecules.
Direct antiviral activity by CD4
+ T cells seems to be criti-
cal during chronic FV infection while the presence of
virus-specific CD8
+ T cells and virus-neutralizing
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(Figure 2). FV replicates mainly in nucleated erythroid
precursors which are MHC class II-negative, and cytoly-
sis of these cells is only observed as a by-stander effect in
the presence of APCs [12]. However, MHC class II-posi-
tive B cells are the main reservoirs of persistent FV [57]
and are susceptible to CD4
+ T cell-mediated cytolysis.
The mechanisms underlying CD4
+ T-cell mediated kill-
ing during acute and persistent FV infection are not fully
understood. Perforin, granzyme A, and granzyme B are
effector molecules of the granule exocytosis pathway that
are mainly produced by CD8
+ T cells and control acute
FV infection. However, these molecules are not essential
during the chronic phase while Fas-FasL interaction, a
cytotoxic pathway that CD4
+ T cells can use [125,126], is
mandatory for effective control of FV replication during
persistent infection [127].
CD4
+ regulatory T cells in FV infection
Pioneering work using the FV model established that
mice persistently infected with FV display elevated levels
of activated CD4
+CD25
+ natural Tregs with potent inhi-
bitory activity including the suppression of CD8
+ T cell-
mediated killing of FV-induced tumors [60]. Later studies
showed that FV-induced Tregs rapidly suppressed the
function of TCR transgenic, FV-specific CD8
+ T cells
adoptively transferred into chronically infected mice [61]
(Figure 2). Kinetic studies indicated that deterioration in
the ability of effector CD8
+ T cells to produce cytotoxic
molecules and cytokines begins at 2 weeks post infection
FV
mild FV-induced 
splenomegaly
Chronic phase of Friend Virus infection
( > 6 weeks post infection)
FV-infected cells
CD4
Teffector
FV-induced 
splenomegaly
CD8
Teffector
CD4
Tregulatory
Figure 2 Distinct roles for CD4
+ T cell subpopulations in chronic Friend Retrovirus infection. During chronic infection, effector CD8
+ T cell
responses are suppressed by regulatory T cells but a subpopulation of effector CD4
+ T cells prevents virus reactivation. (Blocked lines indicate
inhibition of immune responses or virus replication; the dotted line indicates that this response is suppressed during chronic infection).
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+ Treg expansion is
peaking [62] (Figure 1). The kinetic properties of FV-
mediated Treg expansion and CD8
+ T-cell dysfunction
are not changed by LDV co-infection, and the expansion
of Treg occurs during FV infection but not LDV infection
[62,128]. To investigate the correlation between dysfunc-
tion of effector T cells and expansion of CD4
+ Tregs, the
DEREG mouse was employed. These mice express a
Diptheria Toxin (DT) receptor/GFP fusion gene under
the control of the Foxp3 promoter, which is a transcrip-
tion factor critical for the development and function of
CD4
+ Tregs [129]. Foxp3 expressing cells can be experi-
mentally depleted by treatment with DT. When FV
infected DEREG mice receive DT, it leads to specific
deletion of CD4
+Foxp3
+ Tregs. During acute FV infec-
tion, Treg depletion results in strongly augmented peak
CD8
+ T cell responses, including a rise in the frequency
of FV-specific effector CD8
+ T cells, dramatically
enhanced expression and degranulation of cytotoxic
molecules, and increased in vivo CTL-mediated lysis of
infected target cells [128]. Most importantly, this increase
in CD8
+ T cell activity results in a significant reduction
in virus loads. During chronic FV infection, ablation of
Tregs induces proliferation of FV-specific CD8
+ T cells
as well as reactivation of the residual but functionally
exhausted CD8
+ T cells [39]. Importantly, the reactiva-
tion of the suppressed CD8
+ T cell response in Treg-
depleted mice results in reduced viral set points during
chronic retroviral infection.
CD4
+ natural Tregs also influence the outcome of CD4
+
effector T cell responses during acute FV infection. FV-
specific CD4
+ T cells display anti-viral effector functions
until 2 wpi, but thereafter their ability to produce IFNg is
reduced [67] (Figure 1). These FV-specific CD4
+ T cells
with reduced IFNg expression at 3 wpi regain their ability
to produce IFNg following depletion of CD4
+Foxp3
+
Tregs in infected DEREG mice [67]. Thus, it is evident
that CD4
+ Tregs negatively influence effector functions of
CD4
+ T cells during acute FV infection thereby impairing
initial control over viral replication [67,129]. These find-
i n g sa r es u p p o r t e db yt h ew o r ko fA n t u n e set al., who
showed that bone-marrow pathology observed in FV-
infected lymphopenic mice, which is mediated by FV-spe-
cific CD4
+ T cells is inhibited by Tregs [32].
Expansion of CD4
+ Tregs during FV infection is highly
compartmentalized with CD4
+ Tregs expanding in organs
with high viral replication and associated inflammation.
Interestingly, depletion experiments showed that the pre-
sence of CD8
+ T cells supports the expansion of CD4
+
Tregs in lymphatic tissues such as spleen and bone mar-
row [128]. Likewise, in HIV infection, CD4
+ Tregs expand
predominantly in lymph nodes where the virus replicates
most efficiently and virus-specific CD8
+ T cells accumu-
late. Thus, Treg numbers in lymph nodes correlate very
well with disease progression of HIV infected individuals
[36,55,130]. Moreover, increased expression of aEb7 integ-
rin (CD103) on CD4
+Foxp3
+ Tregs suggests a role of
integrins in compartmentalization of Tregs in FV infection
[62]. Hence, it becomes imperative to investigate local
Treg responses before drawing conclusions on the role of
Tregs in retroviral infections.
In addition to CD8
+ T cells, dendritic cells (DC) also
seem to be involved in the expansion of Tregs. We have
previously shown that FV-infected DCs do not fully
mature and specifically expand Foxp3
+ Tregs in vitro
[131]. This has also been described for HIV-infected DCs
[132] suggesting a possible mec h a n i s mt h a tr e t r o v i r u s e s
may use to increase numbers of Tregs at sites of infection.
If DCs are involved in Treg expansion, one might presume
that they present viral antigens to Tregs that then prolifer-
ate in an antigen-specific manner. However, FV-specific
induced Tregs are undetectable in FV-infected mice either
by using class II tetramers or after adoptive transfer of FV-
specific CD4
+ T cells from TCR transgenic mice [128].
This finding is in agreement with the fact that CD4
+ T-
cell mediated bone-marrow pathology observed in
FV-infected lymphopenic hosts is impeded by immuno-
suppressive natural Tregs that are not specific for FV [32].
Recent findings from LCMV studies may explain these
seemingly contradictory results. Tregs expanding after an
LCMV clone 13 infection are not LCMV-specific, but at
least a fraction of them expand in response to an endogen-
ous retroviral superantigen (Sag) [133]. The chronic
LCMV infection upregulates expression of the Sag in DCs,
which then induce proliferation of Tregs with certain
T cell receptors that can bind Sag. There is experimental
evidence that the percentage of Tregs with the same T cell
receptor (Vb5) increases during FV infection (own unpub-
lished results), so a similar mechanism may also be
involved in the expansion of Tregs after FV infection.
Knowledge about the mechanisms underlying Treg-
mediated immunosupression during FV infection is lim-
ited. Studies using transgen i cm i c eh a v ed e m o n s t r a t e d
that CD4
+CD25
+ T cells isolated from mice chronically
infected with FV suppress IFNg and granzyme B produc-
tion by activated CD8
+ T cells. Suppression occurs in a
direct cell-to-cell contact dependent manner independent
of the presence of APCs [134]. CD4
+ Tregs may do so via
the expression of connexins, which are gap-junction pro-
teins that have been found to be critical for the transfer of
the potent inhibitory second messenger cyclic AMP
(cAMP) into effector T cells [135,136]. In contrast, soluble
factors such as IL-10 and transforming growth factor
(TGF)-b secreted by CD4
+ Tregs do not contribute
towards Treg-mediated immunosuppression in in vitro
and in vivo experiments [61,134]. Furthermore, FV-
induced Tregs do not secrete granzymes, ruling out gran-
zyme-dependent Treg-mediated apoptosis of effector
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FV infected mice is still under investigation. In HIV infec-
tions, immunosuppressive IL-10 production by CD4
+ T
cells has been associated with disease progression, but it is
unclear whether these CD4
+ T cells were Tregs [137]. It
has very recently been shown that Tregs control HIV
replication in activated T cells via a contact-dependent
mechanism involving cAMP [138].
Given the well-established role of Tregs in pathogen
persistence, it is now of great interest to develop therapeu-
tic approaches to manipulate this immunosuppressive sub-
set of cells. Treg functions are reversed by blocking
glucocorticoid-induced tumour necrosis factor receptor
(GITR), a member of the TNF receptor superfamily. GITR
is also a phenotypic marker of CD4
+Foxp3
+ Tregs and it is
highly expressed on Tregs during FV infection [62]. Block-
ade by antibodies leads to heightened production of IFNg
and TNFa by CD8
+ T cells [61]. Antibody-mediated sig-
naling through CD137 (4-1BB), a co-stimulatory molecule
also from the TNF receptor superfamily, renders CD8
+ T
cells resistant to suppression by Tregs. Thus, anti-CD137
antibody therapy promotes virus-specific CD8
+ Tc e l lp r o -
liferation and development of effector functions to exert
control over chronic FV infections [139]. In vitro experi-
ments with CD8
+ T cells from HIV-infected patients also
show restored functional properties following treatment
with anti-CD137 antibodies [140].
In mice, an alternative therapeutic approach is the
depletion of Tregs, such as is done experimentally in the
DEREG mouse experiments [39,58,128]. Depletion of
Tregs leads to concerns that autoimmunity or other
immunopathology might be induced, but transient deple-
tion of Tregs in the DEREG mice is not associated with
detectable immunopathology even during an ongoing anti-
retroviral immune response [128]. Such a therapeutic
approach may be a possible treatment in HIV infected
humans using an IL-2-toxin fusion protein (ONTAK)
[141] that kills CD4
+CD25
+ Tregs by binding to the IL-2
receptor via their expression of CD25. Treatment of can-
cer patients with ONTAK did not induce serious clinical
side effects. Jiang and co-workers performed an interesting
experiment to show that IL-2-toxin fusion protein-
mediated depletion of CD4
+CD25
+ Tregs in HIV-1
infected humanized mice resulted in a significant reduc-
tion of viral loads during acute HIV infection [142]. How-
ever, it is not known whether the reduction of viral loads
is mediated by an enhanced immune response.
In addition to HIV, Treg-mediated dysfunction of
effector T cells is a matter of concern in other chronic
virus infections such as HCV, HBV, and EBV [143].
Therefore, therapeutic manipulation of Tregs in vivo
with respect to enhancing virus-specific immunity and
balancing immunopathology could have widespread clin-
ical applications.
Conclusion
It has been known for some time that CD4
+ T cells play a
critical role in retroviral immunity, but only recently has
the complexity of this subpopulation begun to be rea-
lized. Several distinct functions ascribed to subpopula-
tions of CD4
+ T cell have now been defined in mouse
retrovirus models. Type 1 helper CD4
+ T cells were
important for the maintenance and survival of effector
CD8
+ T cells, and follicular helper T cells critically sup-
ported antibody responses. CD4
+ T cells with direct anti-
viral activity were also described, mainly during chronic
retroviral infection, but which may be active during acute
infections as well. Concurrent with the kinetics of the
antiviral CD4
+ T cell response during acute retroviral
infection were the expansion and activation of a subpo-
pulation of natural regulatory T cells at sites of infection.
The natural regulatory T cells suppressed effector T cell
responses, which interfered with immune control of virus
replication and contributed to viral chronicity. Similar
findings have also been made in HIV infected humans
and the therapeutic manipulation of regulatory T cells in
vivo with respect to enhancing retrovirus-specific immu-
nity is a new frontier of high interest in the treatment of
viral infections.
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